Talphera, Inc. TLPH
0.74 USD -0.06 (-7.63%)
Regular-session close
0.74 0.00 0.00%
After hours · Nov 19, 4:00 PM ET
0.7302 Day range 0.8032
0.69 52-week range 1.57
- YTD
- -35.18%
- 1 year
- -44.02%
News
seekingalpha.com Talphera, Inc. (TLPH) Q3 2026 Earnings Call Transcript Talphera, Inc. (TLPH) Q3 2026 Earnings Call Transcriptbenzinga.com Talphera Q3 EPS $(0.05) Beats $(0.06) Estimate Talphera (NASDAQ:TLPH) reported quarterly losses of $(0.05) per share which beat the analyst consensus estimate of $(0.06) by 16.67 percent. This is a 54.55 percent increase over losses of $(0.11)…
prnewswire.com Talphera Reports Third Quarter 2026 Financial Results and Provides Business Update Briefing document submitted to FDA for a Sprint Meeting requesting a close of the NEPHRO CRRT study enrollment based on number of patients enrolled as of December 31, 2026 Pivotal NEPHRO study…
prnewswire.com Talphera to Report Third Quarter 2026 Financial Results on Thursday, November 12, 2026 SAN MATEO, Calif., Nov. 4, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative…
defenseworld.net Head to Head Comparison: ANI Pharmaceuticals (NASDAQ:ANIP) and Talphera (NASDAQ:TLPH) Talphera (NASDAQ: TLPH - Get Free Report) and ANI Pharmaceuticals (NASDAQ: ANIP - Get Free Report) are both small-cap healthcare companies, but which is the better stock? We will contrast the two…
zacks.com Talphera (TLPH) Upgraded to Buy: Here's What You Should Know Talphera (TLPH) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
prnewswire.com Talphera to Participate in the H.C. Wainwright 28th Annual Global Investment Conference SAN MATEO, Calif., Sept. 3, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative…
seekingalpha.com Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript Talphera, Inc. (TLPH) Q2 2026 Earnings Call Transcript
prnewswire.com Talphera Announces Second Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study of nafamostat is 75% enrolled; expected to be complete this year Draft 2026 KDIGO guidelines added nafamostat as an acceptable CRRT anticoagulant, a positive change from…
prnewswire.com Talphera to Report Second Quarter 2026 Financial Results on Wednesday, August 12, 2026 SAN MATEO, Calif., Aug. 5, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative…
seekingalpha.com Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript Talphera, Inc. (TLPH) Q1 2026 Earnings Call Transcript
prnewswire.com Talphera Announces First Quarter 2026 Financial Results and Provides Corporate Update NEPHRO CRRT clinical study expected to be completed this year Cash and investments of $21.1 million at March 31, 2026 Conference call and webcast to be held on Wednesday, May 13, 2026 at 4:30 pm ET…
prnewswire.com Talphera to Host First Quarter Financial Results and Corporate Update Call and Webcast on Wednesday, May 13, 2026 SAN MATEO, Calif., May 7, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative therapies…
prnewswire.com Talphera Announces Two Abstracts Accepted for Presentation at AKI & CRRT 2026 SAN MATEO, Calif., March 25, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative…
defenseworld.net Talphera Q4 Earnings Call Highlights Talphera (NASDAQ: TLPH) used a virtual analyst and investor event to provide a business update and to highlight what company leaders and two clinical experts described as an unmet need in…
seekingalpha.com Talphera, Inc. (TLPH) Analyst/Investor Day Transcript Talphera, Inc. (TLPH) Analyst/Investor Day Transcript
prnewswire.com Talphera Announces Fourth Quarter and Full Year 2025 Financial Results and Provides Corporate Update Previously announced achievement of 50% enrollment of the NEPHRO CRRT clinical study in March 2026 and closed the associated financing tranche of $4.1 million All 12 clinical study sites now able to…
prnewswire.com Talphera to Host Virtual Investor & Analyst Event to Discuss Niyad® for Use in Continuous Renal Replacement Therapy (CRRT), on March 23, 2026 SAN MATEO, Calif., March 18, 2026 /PRNewswire/ -- Talphera, Inc. (Nasdaq: TLPH), ("Talphera"), a specialty pharmaceutical company focused on the development and commercialization of innovative…
prnewswire.com Talphera Announces 50% Enrollment Milestone in Ongoing NEPHRO-CRRT Registrational Trial Enrolled 35 of the 70 patients in the ongoing NEPHRO-CRRT registrational study, supported by new target profile sites Company to host a virtual investor and analyst event on March 23 at 11:00 am ET…
defenseworld.net Talphera (NASDAQ:TLPH) Insider Purchases $28,350.00 in Stock Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Badri Dasu purchased 35,000 shares of the business's stock in a transaction on Thursday, February 12th. The shares were purchased at an average…
defenseworld.net Insider Buying: Talphera (NASDAQ:TLPH) Insider Acquires $28,350.00 in Stock Talphera, Inc. (NASDAQ: TLPH - Get Free Report) insider Shakil Aslam purchased 35,000 shares of the company's stock in a transaction dated Thursday, February 12th. The stock was bought at an average…
